Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.

Autor: Çınar OE; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Hematology Unit, Turkey. Electronic address: drerkincinar@gmail.com., Sayınalp B; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Turkey., Aladağ Karakulak E; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Hematology Unit, Turkey., Avşar Karataş A; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Hematology Unit, Turkey., Velet M; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Hematology Unit, Turkey., İnkaya AÇ; Hacettepe University Faculty of Medicine, Department of Infectious Diseases, Turkey., Ersoy Ortaç NE; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Intensive Care Unit, Turkey., Öcal S; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Intensive Care Unit, Turkey., Aksu S; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Hematology Unit, Turkey., Haznedaroğlu İC; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Hematology Unit, Turkey., Sayınalp N; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Hematology Unit, Turkey., Özcebe Oİ; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Hematology Unit, Turkey.
Jazyk: angličtina
Zdroj: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2020 Oct; Vol. 59 (5), pp. 102821. Date of Electronic Publication: 2020 May 29.
DOI: 10.1016/j.transci.2020.102821
Abstrakt: During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our experience of multi-task treatment approach with convalescent immune plasma and anti-cytokine drug combination in a COVID-19 patient with extremely challenging comorbidities including active myeloid malignancy, disseminated tuberculosis and kidney failure.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: